A review of the carbapenems in clinical use and clinical trials

Recent Patents on Anti-Infective Drug Discovery

Volumn 3, Issue 2, 2008, Pages 123-131

  Lo, Tze S ^a   Welch, Justin M ^a   Alonto, Augusto M ^b   Vicaldo Alonto, Eileen A R ^c  

^a Fargo VA Medical Center   (United States)

^b MeritCare Hospital   (United States)

^c Far Eastern University Dr Nicanor Reyes Medical Foundation   (Philippines)

Author keywords

Broad spectrum; Carbapenems; New agents; Nosocomial infection; Resistant organisms

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CEFCAPENE; CEFDITOREN; CEFOTAXIME; CEFTERAM; CEFTRIAXONE; CILASTATIN; CILASTATIN PLUS IMIPENEM; CYCLOSPORIN; DORIPENEM; ERTAPENEM; FROPENEM; GANCICLOVIR; IMIPENEM; MEROPENEM; PANIPENEM; PENICILLIN BINDING PROTEIN; PENICILLIN G; PROBENECID; PZ 601; R 49084631; TEBIPENEM; TEBIPENEM PIVOXIL; TOMOPENEM; TYPHOID VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VANCOMYCIN; ANTIINFECTIVE AGENT; NEW DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG STRUCTURE; GASTROINTESTINAL DISEASE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INJECTION SITE REACTION; LUNG INFECTION; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PRURITUS; REVIEW; SEIZURE; SINGLE DRUG DOSE; SKIN INFECTION; THROMBOPHLEBITIS; URINARY TRACT INFECTION; VOMITING; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG INTERACTION; PATENT; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; DRUGS, INVESTIGATIONAL; HUMANS; MOLECULAR STRUCTURE; PATENTS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME;

EID: 52449108840     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489108784746588     Document Type: Review

References (65)

1. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007; 67(7): 1027-1052.
2. Bryskier A. In: Antimicrobial Agents - Antibacterials and Antifungals. Chapter 8: Carbapenems. Washington DC, ASM Press; 2005; 269-318.
3. Kahan JS, Kahan FM, Goegelman R, et al. Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties. J Antibiot (Tokyo) 1979; 32(1): 1-12.
4. Norrby SR. Carbapenems. Med Clin North Am 1995; 79(4): 745-759.
5. Romesberg, F., Cirz, R., Patten, P. A.: WP06108075 (2006).
6. Coleman, J., Han, K.: WO2007103548 (2007).
7. Lister PD. Carbapenems in the USA: focus on doripenem. Expert Rev Anti Infect Ther 2007; 5(5): 793-809.
8. Fish DN. In: Antimicrobial therapy and vaccines. Carbapenems. Baltimore, MD, Williams & Wilkins; 1999; 690-703.
9. Hagerman JK, Knechtel SA, Klepser ME. Doripenem: a new extended-spectrum carbapenem antibiotic. Formulary 2007; 42: 676-688.
10. Christensen, B. G., Schmitt, S. M., Johnston, D. B. R.: EP0167139 ( 1986).
11. Choi, W. B., Kowalik, E.: WO05123066 (2005).
12. Nicolau DP. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother 2008; 9(1): 23-37.
13. Hellinger WC, Brewer NS. Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Mayo Clin Proc 1999; 74(4): 420-434.
14. Package insert. Primaxin I.V. (Imipenem and cilastatin for injection). Whitehouse Station, NJ: Merck Co., Inc.; 2006 October.
15. Package insert. Merrem I.V. (meropenem for injection). Wilmington, DE: AstraZeneca; 2005 October.
16. Package insert. Invanz (ertapenem for injection). Whitehouse Station, NJ; Merck Co., Inc.; 2007 March.
17. Package insert. Doribax (doripenem for injection) Raritan, NJ: Ortho-McNeil; 2007 October.
18. Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J Antimicrob Chemother 2003; 52(3): 331-344.
19. Zhanel GG, Johanson C, Embil JM, et al. Ertapenem: review of a new carbapenem. Expert Rev Anti Infect Ther 2005; 3(1): 23-39.
20. Dreetz M, Hamacher J, Eller J, et al. Serum bactericidal activities and comparative pharmaco-kinetics of meropenem and imipenemcilastatin. Antimicrob Agents Chemother 1996; 40(1): 105-109.
21. Mor, A., Radzishevsky, I.: US20070032428 (2007).
22. Livermore DM. Mechanisms of resistance to beta-lactam antibiotics. Scand J Infect Dis Suppl 1991; 78: 7-16.
23. Fontana R, Ligozzi M, Pittaluga F, Satta G. Intrinsic penicillin resistance in enterococci. Microb Drug Resist 1996; 2(2) 209-213.
24. Neuwirth C, Siebor E, Duez JM, Pechinot A, Kazmierczak A. Imipenem resistance in clinical isolates of Proteus mirabilis associated with alterations in penicillin-binding proteins. J Antimicrob Chemother 1995; 36(2): 335-42.
25. Babic M, Hujer AM, Bonomo RA. What's new in antibiotic resistance? Focus on beta-lactamases. Drug Resist Updat 2006; 9(3): 142-156.
26. Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005; 352(4): 3803-91.
27. Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms. Diagn Microbiol Infect Dis 2005; 52(1): 71-74.
28. National Committee for Clinical and Laboratory Standards. In: CLSI Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement M100-S15. Wayne, PA Clinical Laboratory Standards Institute; 2005.
29. Ge Y, Wikler MA, Sahm DF, Blosser-Middleton RS, Karlowsky JA. in vitro Antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother 2004; 48(4): 1384-1396.
30. Jacoby GA, Mills DM, Chow N. Role of bcta-lactamases and porins in resistance to ertapenem and other beta-lactams in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48(8): 3203-206.
31. El Amin N, Giske CG, Jalal S, Keijser B, Kronvall G, Wretlind B. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates. APMIS 2005; 113(3): 187-196.
32. Sanders CC, Sanders WE Jr, Thomson KS, Iaconis JP. Meropenem: activity against resistant gram-negative bacteria and interactions with beta-lactamases. J Antimicrob Chemother 1989; 24 Suppl A: 187-196.
33. Asbel LE, Levison ME. Cephalosporins, carbapenems, and monobactams. Infect Dis Clin North Am 2000; 14(2): 435-447.
34. Kaeaeriaeinen, S., Wickstrand, N., Koski, P.: WO07147945 (2007).
35. Mansour, T. S., Venkatesan, A. M.: WO07030166 (2007).
36. Balkovec, J. M., Greenlee, M. L., Olson, S., Rouen, G. P.: EP1227721 ( 2002).
37. Gotoh N, Tanaka S, Nishino T. Permeability of the outer membrane of Moraxella catarrhalis for beta-lactam antibiotics. J Antimicrob Chemother 1992; 29(3): 279-285.
38. Calandra G, Lydick E, Carrigan J, Weiss L, Guess H. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med 1988; 84(5): 911-918.
39. Faulds D, Heel RC. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalo-virus infections. Drugs 1990; 39(4): 597-638.
40. Norrby SR, Gildon KM. Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem. Scand J Infect Dis 1993; 31(1): 3-10.
41. Teppler H, Gesser RM, Friedland IR, et al. Safety and tolerability of ertapenem. J Antimicrob Chemother 2004; 53 Suppl 2: ii75-81.
42. Ong C, Chua AC, Tambyah PA, Fei YS. Seizures associated with ertapenem. Int J Antimicrob Agents 2008; 31(3): 290.
43. Lunde JL, Nelson RE, Storandt HF. Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy. Pharmacotherapy 2007; 27(8): 1202-1205.
44. Saidel-Odes L, Borer A, Riesenberg K, Smolyakov R, Schlaeffer F. History of cerebrovascular events: a relative contraindication to ertapenem treatment. Clin Infect Dis 2006; 43(2): 262-263.
45. Seto AH, Song JC, Guest SS. Ertapenem-associated seizures in a peritoneal dialysis patient. Ann Pharmacother 2005; 39(2): 352-356.
46. Shah PM, Isaacs RD. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 2003; 52(4): 538-542.
47. Odink, D. A., Truex, P. F., Ge, Y.: U520050065141 (2005).
48. Lepper PM, Grusa E, Reichl H, Hogel J, Trautmann M. Consumption of imipenem correlates with beta-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46(9): 2920-925.
49. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43(6): 1379-82.
50. Quale J, Bratu S, Landman D, Heddurshetti R. Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. Clin Infect Dis 2003; 37(2): 214-220.
51. Turner PJ. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagn Microbiol Infect Dis 2008; 60(2): 185-192.
52. Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32 Suppl 2: S146-155.
53. Wang Y, Bolos J, Serradell N. Tebipenem Pivoxil/Tebipenem. Drugs Fut 2006; 31(8): 676.
54. Kobayashi R, Konomi M, Hasegawa K, Morozumi M, Sunakawa K, Ubukata K. in vitro Activity of tebipenem, a new oral carbapenem antibiotic, against penicillin-nonsusceptible Streptococcus pneumoniae. Antimicrob Agents Chemother 2005; 49(3): 889-94.
55. Sakata H. Relationship between protein binding and antimicrobial activities of antibiotics against Streptococcus pneumoniae and Haemophilus influenzae. Science Links Japan [Online] 2006 [access date]: 2008 March 7] Available from URL: http://sciencelinks.jp/j-east/ article/200623/000020062306A0919819.php.
56. Revill P, Serradell N, Bolos J. Tomopenem. Drugs of the Future 2007; 32(1): 37.
57. Sugihara K, Ishii Y, Tateda K, Yamaguchi K. Abstract C1-92: Carbapenemase stability of CS-023 (RO4908463) and other carbapenems. In: 47th ICAAC; 2007 September 17-20; Chicago, IL; 2007.
58. Macgowan AP, Bowker KE, Noel AR. The pharma-codynamics of the antibacterial effect and emergence of resistance to Tomopenem (formerly R04908463/CS-023) in an in vitro pharmacokinetic model of Staphylococcus aureus infection. Antimicrob Agents Chemother [Online] 2008 [access date: 2008 March 4] Available from URL: http://aac.asm.org/cgi/content/abstract/AAC.01153o7v1.
59. Sugihara K, Tateda K, Shibuya R, Yumoto S, Iwata M, Yamaguchi K. Abstract E-271: In vitro activity of CS-023 (RO4908463) against recent clinical isolates of gram-positive and gram-negative pathogens in Japan. In: 47th ICAAC; 2007 September 17-20; Chicago, IL; 2007.
60. Tanaka K, Mikamo H, Nakao K, Watanabe K. Abstract E-270: In vitro Activity of CS-023 (RO4908463) against anaerobic bacteria. In: 47th ICAAC; 2007 September 17-20; Chicago, IL; 2007.
61. Young CL, Rusca A. AFD Di Stefano e. a. Abstract A-39: Safety and multiple dose pharmocokinetics of intravenous PZ-601 (SMP-601): a novel carbapenem. In: 47th ICAAC; 2007 September 17-20; Chicago, IL; 2007.
62. Bryskier A. In: antimicrobial agents - antibacterials and antifungals. Chapter 9: Penems. Washington DC, ASM Press; 2005; 319-335.
63. Gettig JP, Crank CW, Philbrick AH. Faropenem medoxomil. Ann Pharmacother 2008; 42(1): 80-90.
64. Dalhoff A, Thomson CJ. The art of fusion: from penams and cephems to penems. Chemotherapy 2003; 49(3): 105-120.
65. Hamilton-Miller JM. Chemical and microbiologic aspects of penems, a distinct class of beta-lactams: focus on faropenem. Pharmacotherapy 2003; 23(11): 1497-1507.